ALK's Partner, Torii Pharmaceutical, Reports Positive Phase II/III Trial Results for Japanese Cedar SLIT-tablet

ALK

today announced that its partner for Japan, Torii Pharmaceutical Co., Ltd. , has reported positive results from its Phase II/III trial into a sublingual allergy immunotherapy tablet (SLIT-tablet) for Japanese cedar tree pollen allergic rhinitis (hay fever). The trial met its primary efficacy endpoint providing statistically significant improvement in the 'Total Combined Rhinitis Score' (TCRS) compared with patients who received placebo, demonstrating that the SLIT-tablet reduced symptoms of Japanese cedar pollen allergic rhinitis. The trial also showed that the treatment was well tolerated and had a favourable safety profile. ALK's President and CEO Jens Bager said: "These results mark another step on our journey towards globalising ALK's portfolio of SLIT-tablets. Our partnership with Torii continues to progress rapidly and we are getting closer to a launch of these products in the world's second largest pharmaceutical market." The randomised, placebo-controlled, double-blind, comparative trial, which included approximately 1,000 subjects, was initiated in 2014 to investigate the safety and efficacy of the SLIT-tablet in patients with Japanese cedar tree pollen allergic rhinitis. Torii will now proceed with the preparations for a submission of a New Drug Application to